Clinical Trial Update: A Protocol to Allow Treatment With ICL670 for Patients With or at Risk of Life-threatening Complications of Transfusional Iron Overload Who Are Unable to Tolerate Other Iron Chelators Because of Documented Severe Toxicity [Phase 2]

View source ↗

Summary

A Phase 2 protocol update from Novartis to allow treatment with ICL670 for patients with life-threatening transfusional iron overload who cannot tolerate other …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Transfusional Iron Overload

Drugs mentioned

• ICL670

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Transfusional Iron Overload | Phase 2 | Status: COMPLETED